

References

I-264

1. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. *Lancet Oncol.* 2021;22(1):107-117.
2. Adstiladrin® (nadofaragene firadenovec-vncg), suspension for intravesical use [package insert]. Ferring Pharmaceuticals. Kastrup, Denmark. Revised 12/2022.
3. Clinical Pharmacology™ Compendium 2024. Tampa FL: Gold Standard, Inc. Nadofaragene firadenovec-vncg.
4. Micromedex DrugDex Compendium®. 2024. Nadofaragene firadenovec-vncg.
5. National Comprehensive Cancer Network (NCCN). Nadofaragene firadenovec-vncg. NCCN Drugs and Biologics Compendium®. 2024.